Taltz (ixekizumab)


Taltz (ixekizumab) is a medication used for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.




Eli Lilly Nederland B.V.




  • European Medical Agency (EMA)

  • Food and Drug Administration (FDA)

  • Health Canada

  • Therapeutic Goods Administration (TGA)


  • Over 1.2 million patients reached

  • More than 11,000 patients helped

  • 100% successful deliveries to 88 countries


We are experts in import regulations.

Taltz (ixekizumab) for saleBuy Taltz (ixekizumab) online

What is Taltz (ixekizumab) for?

Taltz (ixekizumab) is a monoclonal antibody indicated for the treatment of people with:

  • moderate to severe plaque psoriasis[2,3,4] who are candidates for systemic therapy[2,3,4] or phototherapy[2,3]
  • Active psoriatic arthritis[2,4] in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies[4].

How does Taltz (ixekizumab) work?

The active ingredient in Taltz, ixekizumab, is a humanised interleukin-17A antagonist[2]; a protein designed to attach to interleukin 17A, a messenger molecule in the immune system.

Interleukin 17A is involved in immune system effects, including inflammation, that cause psoriasis[1] and psoriatic arthritis. By attaching to interleukin 17A, ixekizumab blocks its action and reduces the activity of the immune system, thereby reducing the symptoms of psoriasis[1] and psoriatic arthritis.

Where has Taltz (ixekizumab) been approved?

Taltz (ixekizumab) was approved by:

  • Food and Drug Administration (FDA), USA:
    • March 22, 2016, for plaque psoriasis[2]
    • December 1, 2017, for psoriatic arthritis[8]
  • European Medical Agency (EMA), European Union:
    • May 2, 2016, for plaque psoriasis[1]
    • January 11, 2018, for psoriatic arthritis[1]
  • Therapeutic Goods Administration (TGA), Australia, September 6, 2016, for plaque psoriasis[3]
  • Health Canada, August 11, 2016, for plaque psoriasis[10]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Taltz (ixekizumab) taken?

The standard dosage for plaque psoriasis is:

  • first dose of 160 mg (two subcutaneous injections)
  • for the first 12 weeks: a subcutaneous injection of 80 mg every 2 weeks
  • thereafter a subcutaneous injection of 80 mg every 4 weeks.

The standard dosage for psoriatic arthritis is:

  • first dose of 160 mg (two subcutaneous injections)
  • thereafter a subcutaneous injection of 80 mg every 4 weeks.

Taltz (ixekizumab) is provided as a prefilled syringe or a prefilled pen. Instruction for the use of the prefilled syringe and the prefilled pen can be found in our resources section[5,6].

Complete information about Taltz (ixekizumab) dosage and administration can be found in the official prescribing information listed in our references section[2,3,4].

Please consult with your treating doctor for personalised dosing.

Are there any known side effects of Taltz (ixekizumab)?

Common side effects

The most common side effects listed in the prescribing information include[2,3,4]:

  • injection site reactions
  • upper respiratory tract infections
  • nausea (feeling sick)
  • tinea infections (superficial fungal infection of the skin)

Serious side effects

The serious side effects listed in the prescribing information include[2,3,4]:

  • serious infections
  • hypersensitivity (serious allergic reaction)
  • inflammatory Bowel Disease

Use in a specific population

Taltz (ixekizumab) must not be given to patients with active tuberculosis (TB). Anti-TB therapy should be considered in patients with latent TB prior to initiation of treatment.

There is a limited knowledge about the use of ixekizumab in pregnant women. As a precautionary measure, it is preferable to avoid the use of Taltz during pregnancy and use of effective contraception during treatment and for at least 10 weeks after treatment is recommended.

Breast-feeding should be avoided during treatment.

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information[2,3,4].


  1. EMA. Human Medicines: Taltz (ixekizumab)
    cited March 2017
  2. Summary of Product Characteristics [FDA]: Taltz (ixekizumab)[PDF]
    Eli Lilly and Co., Dec. 2017.
  3. Summary of Product Characteristics [TGA]: Taltz (ixekizumab)[PDF]
    Eli Lilly Australia Pty. Ltd., Apr. 2017.
  4. Summary of Product Characteristics [EMA]: Taltz (ixekizumab), [PDF]
    Eli Lilly Nederland B.V., Feb. 2018.
  5. Instructions for use: Taltz (ixekizumab) prefilled syringe[PDF]
  6. Instructions for use: Taltz (ixekizumab) prefilled pen[PDF]
  7. Chow C., et al. Comparison of three methods for measuring psoriasis severity in clinical studies(Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician’s Global Assessment and Lattice System Physician’s Global Assessment.
    J Eur Acad Dermatol Venereol. 2015 Jul.; 29 (7):1406–1414.
  8. Drugs@FDA:FDA Approved Drug Products: Taltz (ixekizumab)
    cited on 16/02/2018
  9. Pincus T. The American College of Rheumatology (ACR) Core Data Set and derivative “patient only” indices to assess rheumatoid arthritis
    Clin Exp Rheumatol 2005; 23(39):109–113.
  10. Product monograph [Health Canada]: Taltz (ixekizumab), [PDF]
    Eli Lilly Canada, Feb. 2020.

This content has been reviewed by a Medical Doctor.

TALTZ (IXEKIZUMAB) Package Prefilled syringe or autoinjector

2 prefilled syringes or pens of 80 mg, 3 prefilled syringes or pens of 80 mg


There are no reviews yet.

Be the first to review “Taltz (ixekizumab)”

Your email address will not be published. Required fields are marked *

Shopping Cart